Abstract

A retrospective analysis of clinical profile of the patients positive for antiphospholipid antibodies (150) that are lupus anticoagulant (83) and anticardiolipin antibodies (57) was carried out from January 2015 to December 2016 in Kasturba Medical College, Manipal. The diagnosis of lupus anticoagulants was based on prolongation of dRVVT, its absence of correction with normal plasma and correction by phospholipids. The presence of antiardiolipin antibodies was based on the technique ELISA (uolmmun). Out of 150 patients positive for antiphospholipid antibodies, the mean age of presentation was 38 years, more commonly seen in the women. The frequency of thrombosis in patients positive for lupus anticoagulants was 55.5% (46), more commonly of venous origin and in the lower limbs. The frequency of patients with lupus anticoagulants presenting with abortion was 26 (31.3%), immune thrombocytopenic purpura, was 80% (67), valvular heart disease was 5 (6%), 35 (42.1%) patients had secondary LA due to autoimmune diseases like SLE, Sjogerns, APS. Anticardiolipin antibodies were present in 57 patients, more common in women. Thrombosis was seen in 28 (49%) patients, more of venous origin and in the lower limbs. Other clinical manifestations were abortions seen in 8 (9%) patients, immune thrombocytopenic purpura seen in 18 (32.5%) patients, valvular heart diseases seen in 8 (14%) of the patients and autoimmune diseases seen in 31.3% of the patients. Patients positive for both lupus anticoagulant and anticardiolipin antibodies (10) had a higher rate of thrombosis around 60%, more commonly of venous origin and had higher associations with autoimmune diseases (80%).

• 1.   Conley CL, Hartman RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–22.
• 2.   Feinstein DI, Rappaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972;1:75–95.
• 3.   Mersky C. Pathogenesis and treatment of altered blood coagulability in patients with malignant tumours. Ann NY Acad Sci. 1974;230:289–93.
• 4.   Vaarala O, Palosno R, Kleemoia M, et al. Autocardiolipin response in acute virus infections. Clin Immunol Immunopath. 1986;41:8.
• 5.   Jagan U. Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection. Am Ann Haematol. 1993;67:95–99.
• 6.   Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990;112:682–98.
• 7.   Bhattacharya M. Clinicohematologic Spectrum in Patientswith Lupus Anticoagulant. Clin Appl Thromb. Hemost. 2005 Apr;11(2):191-5.
• 8.   Shauna S Runchey. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. British Journal of Haematology. 2002, 119(4):1005–10.
• 9.   Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003 Mar 3;101(5):1827–32.
• 10.   Tarek MO, Fat-Hiya MQ, Roberts GT, et al. Single centre review of clinicopathological characterization in 77 patients with positive lupus anticoagulant antibodies. Hematology. 2003;8:249.
• 11.   Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome. Arthritis Rheum. 2002;46:1019–27.
• 12.   O Lima F, Khamashta MA, Buchanan NMM, et al. A study of sixty pregnancies in patients with antiphospholipid syndrome. Clin Exp Rheumatol. 1996 Mar–Apr;14(2):131–36.
• 13.   Lee RM, Silver RM. Recurrent pregnancy loss: Summary and clinical recommendations. Semin Reproduc Med. 2000;8:433.